Importantly, we show that PAD is an effective therapeutic regimen that can be extended to the most prevalent HR‐defective genotypes in PDAC including ATM, BRCA1, BRCA2 and PALB2 in a preclinical setting. This evidence concerns the gene BRCA2 and peripheral arterial disease.